heading lower

This should be trading much closer to book value. Pipeline seems overvalued. The share price should better reflect the risky and long-term nature of drug development.

Expect it to settle around the $1 mark, and then trade sideways from there. The Evogenix merger will probably cut 20 to 30% off the combined entity, as I believe the premium paid was excessive.